Clinical Trial

A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease. The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease. A secondary objective is to further assess the efficacy of TEV-53408 in adults with celiac disease. The expected trial duration per participant is approximately 86 weeks.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-09
Trial Details
NCT Number NCT06807463
Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC
Conditions Celiac Disease
Enrollment 50 participants
Start Date 2025-03-31
Primary Completion 2026-09-15 (estimated)
Study Completion 2027-09-14 (estimated)
Updated on ClinicalTrials.gov 2026-07-27